delfidiagnostics.comHealthcare / Digital HealthFounded: 2019Funding to Date: $652.94MM
Delfi Diagnostics is a biotechnology company with a mission to use its technology for early cancer detection. By developing AI and ML algorithms, Delfi Diagnostics offers predictive testing processes with the goal of maximizing patient survival rates. The company specializes in the detection of breast cancer and aims to help healthcare organizations minimize treatment toxicity with less-invasive treatments. Delfi Diagnostics was founded by Alessandro Leal and Victor Velculescu in 2019 and is headquartered in Baltimore, MD.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
07/18/2022 | Series B | $225MM | $xx.xx | $685.11MM | Av8 Ventures, Brown Advisory, Cowen Healthcare Investments, Dfj Growth, Eli Lilly & Company, Foresite Capital, Illumina Ventures, Initiate Ventures, Menlo Ventures, Northpond Ventures, Open Field Capital, Orbimed, Osage University Partners, Point72, Point Field Partners, Ptx Capital, Rock Springs Capital, Samsara Biocapital, T. Rowe Price Associates, Windham Venture Partners | |
Price per Share
$xx.xx
Shares Outstanding
46,434,241
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Av8 Ventures, Brown Advisory, Cowen Healthcare Investments, Dfj Growth, Eli Lilly & Company, Foresite Capital, Illumina Ventures, Initiate Ventures, Menlo Ventures, Northpond Ventures, Open Field Capital, Orbimed, Osage University Partners, Point72, Point Field Partners, Ptx Capital, Rock Springs Capital, Samsara Biocapital, T. Rowe Price Associates, Windham Venture Partners
|
||||||
01/12/2021 | Series A | $95.97MM | $xx.xx | $170.56MM | Av8 Ventures, Cowen Healthcare Investments, Foresite Capital, Illumina Ventures, Menlo Ventures, Northpond Ventures, Orbimed, Rock Springs Capital, Samsara Biocapital, T. Rowe Price Associates, Windham Venture Partners | |
Price per Share
$xx.xx
Shares Outstanding
46,272,896
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Av8 Ventures, Cowen Healthcare Investments, Foresite Capital, Illumina Ventures, Menlo Ventures, Northpond Ventures, Orbimed, Rock Springs Capital, Samsara Biocapital, T. Rowe Price Associates, Windham Venture Partners
|
||||||
08/12/2019 | Series Seed | $5.5MM | $xx.xx | $11MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
7,180,334
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|